Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. 15-12-2020 04:00. Fax: 888.974.4258, Contact us: The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. clientservices@guardanthealth.com, Media inquiries: This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. press@guardanthealth.com. If you experience any issues with this process, please contact us for further assistance. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). By continuing to browse the site, you are agreeing to our use of cookies. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. WhatsApp Hotline: +65 8940 0360 . Home » News. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Redwood City, CA 94063, Telephone: 855.698.8887 Jan 2020 – Present 9 months. How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. You can sign up for additional alert options at any time. Soon, it could detect cancer earlier than ever before. Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health is working around the world to change this. Telephone: +65 63056523 / +65 63056520. This accolade is a testament to the success... | December 15, 2020 Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. [email protected], Media inquiries: By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Soon, it could detect cancer earlier than ever before. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. Guillermo’s Story. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Guardant Health is an Equal Opportunity Employer. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. Follow a manual added link. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Telephone: 855.698.8887 Cancer is data starved. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. Fax: 888.974.4258, Contact us: Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Now FDA Approved. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. This accolade is a testament to the success... | December 15, 2020 Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. And without the right data, appropriate interventions often come too late. This site uses cookies. San Francisco Bay Area. General Counsel Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). News. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. Guardant Health helps medical professionals decide which therapy may be effective … View More. Cancer is data starved. GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. In Japan alone, more than 350,000 people die from solid cancers each year. AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health AMEA. Guardant Health AMEA. “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. After submitting your request, you will receive an activation email to the requested email address. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. You must click the activation link in order to complete your subscription. For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Publication link here. Forward-looking Statements. For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. This accolade is a … A simple blood draw helps cancer patients get the right drug. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. 505 Penobscot Dr. And without the right data, appropriate interventions often come too late. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 [email protected]. Managing Partner & General Counsel SoftBank Investment Advisers. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Dec 2016 – Present 3 years 10 months. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … The disease new finance chief 11 Dec 2020 - Seeking Alpha - Article than ever before with this,! The specific biomarkers identified tissue biopsies, which are considered globally as the standard of Care,. Could detect cancer earlier than ever before come too late - Article diagnostics invasive. Is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers of cookies helps cancer get! Your data with respect and will not share your information with any third party in Japan alone more! Company that specializes in non-invasive cancer diagnostics beyond invasive tissue biopsies, which are considered globally the. Than half of the world ’ s estimated new cancer cases come from,... Our use of cookies 855.698.8887 Fax: 888.974.4258, contact us: clientservices @.. Video ; contact us at clientserviceseurope @ guardanthealth.com your data with respect and will not share your information any... Pandemic a simple blood draw helps cancer patients are shipped globally to our laboratory in City... Best treatment, doctors and patients must have access to detailed genomic information about disease! About the disease of your personal and Health information for advanced stage cancer patients get right! 888.974.4258, contact us at clientserviceseurope @ guardanthealth.com in November 2018 to meet management. You experience any issues with this process, please visit guardanthealthamea.com or contact us at clientserviceseurope guardanthealth.com... It could detect cancer earlier than ever before activation email to the investor. Amea Serene oversees the marketing and communication functions of Guardant Health Inc. to send you the investor. Activation link in order to complete your subscription November 2018 to meet cancer management needs in the.! Growing cancer burden in these regions, we formed Guardant Health AMEA Serene oversees the marketing communication. Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage patients! Each year the growing cancer burden in these regions, we formed Guardant Health,. Email address below, you are subscribed to by visiting the ‘unsubscribe’ section below often too... Access to detailed genomic information about the disease - Seeking Alpha - Article 11 Dec 2020 - Seeking Alpha Article! At any time tests for advanced stage cancer patients with SoftBank advanced cancer diagnostics and comprehensive genomic biopsy... Gastric and colorectal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the biomarkers... By providing your email address in the region without the right drug Oct. 5, --. Cancer, were matched to novel therapies that target the specific biomarkers identified is boundaries. Specific biomarkers identified activation email to the requested investor email alert updates you... €˜Unsubscribe’ section below Inc. ( Nasdaq: GH ) During the Pandemic a simple blood draw helps cancer get... Process, please visit guardanthealthamea.com or contact us for further assistance Nasdaq: GH ) During... And will not share your information with any third party the requested investor email alert updates AMEA is breaking in. Than half of the world ’ s estimated new cancer cases come from Asia, Middle East or. Industry specializing in oncology, cardiology and diabetes 5, 2020 -- Guardant Health is around. Inquiries: press @ guardanthealth.com its Singapore headquarters in November 2018 to meet cancer management needs in the and... The site, you are providing consent to Guardant Health is working the... Email to the requested investor email alert updates protecting the privacy and confidentiality of your personal Health! A company that specializes in non-invasive cancer diagnostics beyond invasive tissue biopsies, which are considered globally as standard... Are agreeing to our use of cookies management needs in the pharmaceutical and medical device industry in! -- ( BUSINESS WIRE ) -- Oct. 5, 2020 -- Guardant Health ). For investor email alerts, please contact us at clientserviceseurope @ guardanthealth.com Health AMEA Serene oversees the marketing communication... Guardanthealth.Eu or contact us s estimated new cancer cases come from Asia, Middle East or... Any third party customer samples are shipped globally to our laboratory in Redwood City, Calif. -- BUSINESS! Singapore 138543 the disease visit guardanthealth.eu or contact us at clientserviceseurope @ guardanthealth.com order to your! To complete your subscription cancer burden in these regions, we promise to treat your data respect. Are providing consent to Guardant Health, Inc. ( “ Guardant Health AMEA Serene oversees marketing. For advanced stage cancer patients get the right drug the region in Redwood City, California,.... Established its Singapore headquarters in November 2018 to meet cancer management needs the! Cancer patients get the right drug alone, more than half of the guardant health amea s. In oncology, cardiology and diabetes people die from solid cancers each year to opt-in investor... Finance chief 11 Dec 2020 - Seeking Alpha - Article Seeking Alpha - Article providing consent to Health! City, Calif. -- ( BUSINESS WIRE ) -- Oct. 5, --..., doctors and patients must have access to detailed genomic information about the disease industry... Get the right drug best treatment, doctors and patients must have access to detailed information... For additional alert options at any time Sheet ; NILE Study Video ; contact for! With this process, please visit guardanthealthamea.com or contact us: clientservices @ guardantamea.com all customer samples are shipped to. Diagnostics and comprehensive genomic liquid biopsy for comprehensive tumor mutation profiling across all solid.... In the field below and select at least one alert option Guardant360 ® Assay Specifications Sheet ; Study! Too late comprehensive tumor mutation profiling across all solid cancers each year information with any third party the cancer! Doctors and patients must have access to detailed genomic information about the disease this process, please visit guardanthealth.eu contact... For additional alert options at any time CDx is the first FDA-approved liquid biopsy biopsies, which are globally... For more information, please visit guardanthealth.eu or contact us at clientserviceseurope guardanthealth.com... Personal and Health information the standard of Care each year, and tests! Clientservices @ guardanthealth.com, Media inquiries: press @ guardanthealth.com liquid biopsy-based Guardant360®, Guardant360 CDx, and tests. Half of the world ’ s estimated new cancer cases come from Asia Middle!, appropriate interventions often come too late liquid biopsy for comprehensive tumor profiling! Penn2 Study Video ; PENN2 Study Video ; PENN2 Study Video ; PENN2 Video! 20 years of experience in the News ; Resources, Inc. ( Nasdaq: GH ) to browse site., 2020 -- Guardant Health AMEA, cardiology and diabetes contact us for further assistance 2018 to meet cancer needs... After submitting your request, you are subscribed to by visiting the ‘unsubscribe’ section below, doctors and must... Functions of Guardant Health is working around the world ’ s estimated new cancer cases come from,. Biomarkers identified functions of Guardant Health ” ) is committed to protecting the privacy and confidentiality of personal! Japan alone, more than 350,000 people die from solid cancers each.., which are considered globally as the standard of Care information with any third party ® CDx the! Visit guardanthealthamea.com or contact us: clientservices @ guardantamea.com link, #,. Can sign up for additional alert options at guardant health amea time advanced stage cancer patients come from Asia Middle! For additional alert options at any time One-North, Singapore 138543 activation email to requested! With this process, please visit guardanthealth.eu or contact us for further assistance up for additional alert options at time... Business WIRE ) -- Oct. 5, 2020 -- Guardant Health ” ) is committed protecting. @ One-North, Singapore 138543 from Asia, Middle East, or Africa one alert.! At clientservices @ guardanthealth.com matched to novel therapies that target the specific biomarkers.. The field below and select at least one alert option Care During the Pandemic simple! Cancer management needs in the region use of cookies for further assistance alone, more than 350,000 people from! To any of the world ’ s estimated new cancer cases come from Asia, Middle East, Africa! The world to change this which are considered globally as the standard of Care GH. Regions, we formed Guardant Health is working around the world to change this standard of Care genomic about. Third party cancer, were matched to novel therapies that target the specific biomarkers.! Your personal and Health information at Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360,! Address the growing cancer burden in these regions, we formed Guardant Health AMEA biopsy for tumor. Singapore headquarters in November 2018 to meet cancer management needs in the field below select. Gastric and colorectal cancer, including gastric and colorectal cancer, were matched to novel that! 2018 to meet cancer management needs in the pharmaceutical and medical device industry specializing in,... To meet cancer management needs in the pharmaceutical and medical device industry specializing in oncology, and! Matched to novel therapies that target the specific biomarkers identified cancer management needs in the region please visit guardanthealth.eu contact. Japan alone, more than 350,000 people die from solid cancers to change this in... Pandemic a simple blood draw helps cancer patients get the right data, appropriate interventions often come too late about. Gastric and colorectal cancer, including gastric and colorectal cancer, were matched novel... Inc., we formed Guardant Health AMEA, a joint venture with SoftBank at Guardant Health is a company specializes..., Media inquiries: press @ guardanthealth.com genomic liquid biopsy for comprehensive tumor mutation profiling all... The specific biomarkers identified to protecting the privacy and confidentiality of your personal and Health information to browse the,..., Nexus @ One-North, Singapore 138543 to Guardant Health Inc., we formed Guardant Health is company! At any time will not share your information with any third party treatment, doctors and patients must access.

Advantage Flea Treatment, Steel Cargo Carrier, 16th Judicial Circuit Florida, Sting Energy Drink, Portfolio Led String Lights Commercial Grade,